Renowned, experienced industry leader in newly created role for Cytiva

Pierre-Alain Ruffieux joins Cytiva executive team on 1 July 2024 as Chief Operating Officer. Cytiva is strengthening its leadership team with one of the biotechnology industry’s most highly regarded and experienced leaders, Pierre-Alain Ruffieux, who will join as Chief Operating Officer.

Pierre-Alain Ruffieux joins Cytiva as Chief Operating Officer

Ruffieux will come onboard 1 July. He will be responsible for orchestrating Cytiva’s global operations and supply chain, which processes an average of 30 000 orders per month, providing customers with critical technologies and services across more than 80 countries.

Pierre-Alain Ruffieux says:

“I am honored to join Cytiva in this role. The company mission resonates deeply with my personal passion for innovation and operational excellence. As a former customer, I’ve always admired the exceptional quality and reliability of Cytiva’s products and services. Leveraging this firsthand experience and working closely with Cytiva’s talented team, I look forward to further enhancing our customer experience and fostering sustainable global growth.”

Chris Riley, Cytiva CEO and Danaher Executive Vice President, says:

“We’re excited for what Pierre-Alain will bring to our customers with his depth of experience, expertise, and customer perspective. He has a proven track record from serving as CEO of Lonza, one of our largest customers, as well as Head of Global Pharma Technical Operations at Roche, where he oversaw pharmaceutical commercial manufacturing and supply chain operations. I look forward to working with him to sharpen Cytiva’s ability to deliver with quality and on time to our customers and their patients.”

Cytiva’s evolution since 2020

Since its inception as a Danaher company in 2020, Cytiva has combined with Pall Life Sciences and now provides the industry’s broadest bioprocessing portfolio to researchers, developers, and manufacturers of life-saving therapies. Cytiva materials are used for more than 90% of the therapeutic monoclonal antibodies sold worldwide. Cytiva has grown from 6 000 to 15 000 associates in more than 40 countries, all dedicated to serving our customers as they accelerate their therapies to market.

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma, and contract manufacturers. Learn more at

Media contact:

Dodi Axelson